Identification
NameFenofibrate
Accession NumberDB01039  (APRD00405, DB09545)
TypeSmall Molecule
GroupsApproved
Description

Fenofibrate is a prodrug of fenofibric acid, an antilipemic agent which reduces both cholesterol and triglycerides in the blood.

Structure
Thumb
Synonyms
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Fenofibrato
Fenofibratum
Finofibrate
FNF
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
Procetofen
External IDs Not Available
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntaraCapsule43 mg/1OralLupin Pharma2009-09-25Not applicableUs
AntaraCapsule30 mg/1OralLupin Pharma2013-11-01Not applicableUs
AntaraCapsule130 mg/1OralLupin Pharma2009-09-25Not applicableUs
AntaraCapsule90 mg/1OralLupin Pharma2013-11-01Not applicableUs
Ava-fenofibrate MicroCapsule200 mgOralAvanstra Inc2011-08-222014-08-21Canada
Dom-fenofibrate MicroCapsule200 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Dom-fenofibrate SupraTablet160 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-fenofibrate SupraTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Feno-micro-200Capsule200 mgOralPro Doc Limitee1999-08-27Not applicableCanada
FenofibrateCapsule50 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
FenofibrateTablet40 mg/1OralOceanside Pharmaceuticals2010-11-182016-02-25Us
FenofibrateTablet145 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2004-11-05Not applicableUs
FenofibrateCapsule43 mg/1OralLupin Pharmaceuticals2013-02-22Not applicableUs
FenofibrateTablet48 mg/1OralAvera Mc Kennan Hospital2016-08-29Not applicableUs
FenofibrateTablet145 mg/1OralUnit Dose Services2004-11-05Not applicableUs
FenofibrateTablet145 mg/1Oralbryant ranch prepack2016-02-09Not applicableUs
FenofibrateTablet48 mg/1OralTeva2004-11-05Not applicableUs
FenofibrateTablet145 mg/1OralA S Medication Solutions2016-02-092017-06-20Us
FenofibrateTablet145 mg/1OralZydus Pharmaceuticals Usa, Inc.2004-11-05Not applicableUs68382 0230 16 nlmimage10 1f3c8ff4
FenofibrateTablet48 mg/1OralA S Medication Solutions2004-11-052017-02-17Us
FenofibrateTablet145 mg/1OralCarilion Materials Management2004-11-05Not applicableUs
FenofibrateCapsule50 mg/1OralANI Pharmaceuticals, Inc.2016-04-13Not applicableUs
FenofibrateTablet145 mg/1Oralbryant ranch prepack2016-02-09Not applicableUs
FenofibrateCapsule150 mg/1OralH2 Pharma, Llc2014-05-05Not applicableUs
FenofibrateTablet120 mg/1OralOceanside Pharmaceuticals2010-11-182016-02-25Us
FenofibrateTablet145 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2004-11-05Not applicableUs
FenofibrateCapsule130 mg/1OralLupin Pharmaceuticals2013-02-22Not applicableUs
FenofibrateTablet48 mg/1OralZydus Pharmaceuticals Usa, Inc.2016-02-09Not applicableUs
FenofibrateTablet48 mg/1Oralbryant ranch prepack2016-02-09Not applicableUs
FenofibrateTablet145 mg/301OralNorthwind Pharmaceuticals2014-05-20Not applicableUs00093 2060 98 nlmimage10 072983cc
FenofibrateTablet40 mg/1OralImpax Generics2015-06-24Not applicableUs
FenofibrateTablet48 mg/1OralTeva2016-02-09Not applicableUs
FenofibrateTablet48 mg/1OralNucare Pharmaceuticals, Inc.2016-02-09Not applicableUs
FenofibrateTablet48 mg/1OralCarilion Materials Management2004-11-05Not applicableUs00093 2061 98 nlmimage10 552b2a99
FenofibrateCapsule150 mg/1OralANI Pharmaceuticals, Inc.2016-04-13Not applicableUs
FenofibrateTablet48 mg/1OralZydus Pharmaceuticals Usa, Inc.2004-11-05Not applicableUs
FenofibrateTablet145 mg/1OralZydus Pharmaceuticals Usa, Inc.2016-02-09Not applicableUs
FenofibrateTablet145 mg/1OralTeva2004-11-05Not applicableUs
FenofibrateTablet145 mg/1OralNorthwind Pharmaceuticals2015-04-28Not applicableUs
FenofibrateTablet145 mg/1OralNucare Pharmaceuticals, Inc.2016-02-09Not applicableUs
FenofibrateTablet120 mg/1OralImpax Generics2015-06-24Not applicableUs
FenofibrateTablet145 mg/1OralTeva2016-02-09Not applicableUs
Fenofibrate MicroCapsule200 mgOralSanis Health Inc2010-02-25Not applicableCanada
Fenofibrate-STablet160 mgOralSanis Health Inc2010-11-23Not applicableCanada
Fenofibrate-STablet100 mgOralSanis Health Inc2010-11-23Not applicableCanada
FenoglideTablet120 mg/1OralPhysicians Total Care, Inc.2010-04-28Not applicableUs
FenoglideTablet40 mg/1OralShore Therapeutics, Inc2010-11-18Not applicableUs
FenoglideTablet120 mg/1OralShore Therapeutics, Inc2010-11-18Not applicableUs
FenoglideTablet40 mg/1OralSantarus, Inc..2010-11-18Not applicableUs
FenoglideTablet120 mg/1OralSantarus, Inc..2010-11-18Not applicableUs68012 0495 90 nlmimage10 a649d34e
FenomaxCapsule100 mgOralCipher Pharmaceuticals Inc.Not applicableNot applicableCanada
FenomaxCapsule160 mgOralCipher Pharmaceuticals Inc.2006-11-14Not applicableCanada
Lipidil Cap 100mgCapsule100 mgOralLaboratoires Fournier S.A.S.1990-12-311997-08-11Canada
Lipidil EzTablet48 mgOralBgp Pharma Ulc2005-07-26Not applicableCanada
Lipidil EzTablet145 mgOralBgp Pharma Ulc2005-07-26Not applicableCanada
Lipidil MicroCapsule200 mgOralBgp Pharma Ulc1995-12-312016-11-09Canada
Lipidil Micro - Cap 67mgCapsule67 mgOralLaboratoires Fournier S.A.S.1999-05-272003-07-21Canada
Lipidil SupraTablet160 mgOralBgp Pharma Ulc2000-03-16Not applicableCanada
Lipidil Supra 100 mgTablet100 mgOralLaboratoires Fournier S.A.S.2000-03-162014-01-29Canada
LipofenCapsule150 mg/1OralKowa Company, Ltd.2007-10-01Not applicableUs66869 0147 30 nlmimage10 b83bdc2e
LipofenCapsule50 mg/1OralKowa Company, Ltd.2007-10-01Not applicableUs
Mint-fenofibrate ETablet145 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-fenofibrate MicroCapsule200 mgOralMylan Pharmaceuticals1999-05-26Not applicableCanada
Novo-fenofibrateCapsule100 mgOralNovopharm Limited1998-01-232005-08-10Canada
Novo-fenofibrate MicronizedCapsule200 mgOralNovopharm Limited2001-04-202015-10-26Canada
Novo-fenofibrate MicronizedCapsule67 mgOralNovopharm Limited2001-04-202015-10-26Canada
Ntp-fenofibrate-STablet100 mgOralTevaNot applicableNot applicableCanada
Ntp-fenofibrate-STablet160 mgOralTevaNot applicableNot applicableCanada
Nu-feno-microCapsule67 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-feno-microCapsule200 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-fenofibrateCapsule100 mgOralNu Pharm Inc1996-08-292012-09-04Canada
PHL-fenofibrate MicroCapsule200 mgOralPharmel Inc2003-04-232016-10-25Canada
PHL-fenofibrate SupraTablet100 mgOralPharmel IncNot applicableNot applicableCanada
PHL-fenofibrate SupraTablet160 mgOralPharmel IncNot applicableNot applicableCanada
PMS-fenofibrateCapsule100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-fenofibrate MicroCapsule200 mgOralPharmascience Inc1999-04-192016-10-28Canada
PMS-fenofibrate MicroCapsule200 mgOralPharmascience Inc2005-11-29Not applicableCanada
PMS-fenofibrate SupraTablet100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-fenofibrate SupraTablet160 mgOralPharmascience IncNot applicableNot applicableCanada
Pro-feno-super - 100Tablet100 mgOralPro Doc Limitee2008-07-10Not applicableCanada
Pro-feno-super - 160Tablet160 mgOralPro Doc Limitee2008-07-10Not applicableCanada
Q-fenofibrate MicroCapsule200 mgOralQd Pharmaceuticals Ulc2012-05-292015-08-21Canada
Ran-fenofibrate ETablet145 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Ran-fenofibrate STablet100 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Ran-fenofibrate STablet160 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Ratio-fenofibrate McCapsule200 mgOralTeva2004-04-05Not applicableCanada
Riva-fenofibrate MicroCapsule200 mgOralLaboratoire Riva Inc2003-03-122016-05-31Canada
Sandoz Fenofibrate ETablet48.0 mgOralSandoz Canada Incorporated2012-12-12Not applicableCanada
Sandoz Fenofibrate ETablet145.0 mgOralSandoz Canada Incorporated2012-08-24Not applicableCanada
Sandoz Fenofibrate STablet160 mgOralSandoz Canada Incorporated2007-01-11Not applicableCanada
Sandoz Fenofibrate STablet200 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Fenofibrate STablet100 mgOralSandoz Canada Incorporated2007-01-11Not applicableCanada
Teva-fenofibrate-STablet160 mgOralTeva2007-02-20Not applicableCanada
Teva-fenofibrate-STablet100 mgOralTeva2007-02-20Not applicableCanada
TricorTablet145 mg/1OralA S Medication Solutions2004-11-052017-06-20Us
TricorTablet48 mg/1OralAbbvie2004-11-05Not applicableUs00074 6122 90 nlmimage10 051d829c
TricorTablet145 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-20Not applicableUs
TricorTablet145 mg/1OralAbbvie2016-02-05Not applicableUs
TricorTablet145 mg/1OralPhysicians Total Care, Inc.2004-12-29Not applicableUs
TricorTablet48 mg/1OralCardinal Health2004-11-05Not applicableUs
TricorTablet145 mg/1OralAbbvie2004-11-05Not applicableUs
TricorTablet145 mg/1OralA S Medication Solutions2016-02-052017-06-20Us
TricorTablet48 mg/1OralPhysicians Total Care, Inc.2005-02-16Not applicableUs
TricorTablet145 mg/1OralAphena Pharma Solutions Tennessee, Inc.2004-11-05Not applicableUs00074 6123 90 nlmimage10 c93d64fb
TricorTablet145 mg/1OralCardinal Health2004-11-05Not applicableUs
TricorTablet48 mg/1OralAbbvie2016-02-05Not applicableUs
TricorTablet145 mg/1OralA S Medication Solutions2004-11-052017-06-20Us
TriglideTablet160 mg/1OralShionogi2005-05-07Not applicableUs
TriglideTablet160 mg/1OralCasper Pharma Llc2017-02-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-feno-microCapsule200 mgOralApotex Corporation1999-03-29Not applicableCanada
Apo-feno-micro CapsulesCapsule67 mgOralApotex Corporation2001-02-21Not applicableCanada
Apo-feno-superTablet100 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-feno-superTablet160 mgOralApotex Corporation2006-04-21Not applicableCanada
Apo-feno-superTablet200 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-fenofibrateCapsule100 mgOralApotex Corporation1996-10-02Not applicableCanada
FenofibrateTablet, coated145 mg/1OralNorth Star Rx Llc2017-07-15Not applicableUs
FenofibrateTablet145 mg/1OralPerrigo New York Inc.2014-09-23Not applicableUs
FenofibrateCapsule200 mg/1OralPhysicians Total Care, Inc.2006-06-01Not applicableUs
FenofibrateCapsule43 mg/1OralApotex Corporation2013-07-26Not applicableUs
FenofibrateTablet160 mg/1OralAmerincan Health Packaging2014-10-20Not applicableUs
FenofibrateTablet, film coated48 mg/1OralMylan Institutional2013-06-10Not applicableUs
FenofibrateTablet40 mg/1OralMylan Pharmaceuticals2016-06-23Not applicableUs
FenofibrateCapsule67 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet, film coated54 mg/1OralProficient Rx LP2006-05-10Not applicableUs
FenofibrateCapsule130 mg/1OralRanbaxy Inc.2015-03-02Not applicableUs
FenofibrateTablet54 mg/1OralA S Medication Solutions2010-02-012017-06-20Us
FenofibrateCapsule134 mg/1OralMylan Pharmaceuticals2012-10-23Not applicableUs00378 8629 77 nlmimage10 ff3affd7
FenofibrateCapsule200 mg/1OralCipla Limited2017-03-30Not applicableUs
FenofibrateTablet145 mg/1OralOceanside Pharmaceuticals2012-06-252015-10-31Us68682 0528 01 nlmimage10 943a4a22
FenofibrateTablet145 mg/1OralAv Pak2016-09-19Not applicableUs
FenofibrateCapsule130 mg/1OralMylan Pharmaceuticals2013-02-22Not applicableUs00378 6089 93 nlmimage10 083b0458
FenofibrateTablet160 mg/1OralPreferreed Pharmaceuticals Inc.2016-10-17Not applicableUs
FenofibrateCapsule134 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2017-04-07Not applicableUs
FenofibrateTablet, coated54 mg/1OralKaralex Pharma LLC2009-11-20Not applicableUs
FenofibrateTablet, film coated160 mg/1OralNucare Pharmaceuticals, Inc.2006-05-10Not applicableUs
FenofibrateTablet160 mg/1OralKaiser Foundations Hospitals2011-04-26Not applicableUs
FenofibrateTablet, coated145 mg/1OralAurobindo Pharma2016-05-05Not applicableUs
FenofibrateTablet, film coated160 mg/1Oralbryant ranch prepack2006-05-10Not applicableUs
FenofibrateTablet160 mg/1OralA S Medication Solutions2015-11-232017-06-20Us
FenofibrateTablet54 mg/1OralAidarex Pharmaceuticals LLC2010-02-01Not applicableUs
FenofibrateCapsule67 mg/1OralRhodes Pharmaceuticals, L.P.2017-06-01Not applicableUs
FenofibrateTablet48 mg/1OralAmerincan Health Packaging2013-01-15Not applicableUs68180 0360 09 nlmimage10 17470b88
FenofibrateTablet160 mg/1OralRemedy Repack2016-04-08Not applicableUs
FenofibrateTablet145 mg/1OralLupin Pharmaceuticals2012-07-13Not applicableUs
FenofibrateCapsule67 mg/1OralMylan Pharmaceuticals2012-10-23Not applicableUs00378 8628 77 nlmimage10 003b0008
FenofibrateCapsule134 mg/1OralAv Pak2017-01-10Not applicableUs
FenofibrateCapsule134 mg/1OralCipla Limited2017-03-30Not applicableUs
FenofibrateTablet160 mg/1OralAv Kare, Inc.2015-01-07Not applicableUs
FenofibrateTablet54 mg/1OralAv Pak2015-08-13Not applicableUs
FenofibrateCapsule134 mg/1OralPhysicians Total Care, Inc.2009-02-25Not applicableUs
FenofibrateTablet, film coated160 mg/1OralSt. Marys Medical Park Pharmacy2010-02-01Not applicableUs63304 0901 90 nlmimage10 b105d89e
FenofibrateCapsule134 mg/1OralAmerincan Health Packaging2014-10-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralNorthwind Pharmaceuticals2015-02-24Not applicableUs
FenofibrateTablet, film coated145 mg/1OralCamber Pharmaceuticals2016-07-14Not applicableUs
FenofibrateTablet160 mg/1OralClinical Solutions Wholsesale2010-02-012017-06-24Us
FenofibrateTablet160 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralDirectrx2015-01-01Not applicableUs
FenofibrateTablet54 mg/1OralLupin Pharmaceuticals2015-11-11Not applicableUs
FenofibrateTablet, film coated48 mg/1OralA S Medication Solutions2013-05-212017-06-20Us
FenofibrateTablet, film coated145 mg/1OralMylan Pharmaceuticals2013-05-21Not applicableUs
FenofibrateTablet160 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet145 mg/1OralNucare Pharmaceuticals, Inc.2014-09-23Not applicableUs
FenofibrateTablet160 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-02-01Not applicableUs
FenofibrateTablet, film coated54 mg/1OralRhodes Pharmaceuticals, L.P.2017-06-01Not applicableUs
FenofibrateTablet160 mg/1OralImpax Generics2010-02-01Not applicableUs00115 5522 10 nlmimage10 dd406e83
FenofibrateTablet, film coated54 mg/1OralMylan Pharmaceuticals2009-12-22Not applicableUs00378 7100 77 nlmimage10 d43eea07
FenofibrateTablet145 mg/1OralCipla Limited2016-12-15Not applicableUs
FenofibrateCapsule200 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2017-04-07Not applicableUs
FenofibrateTablet, coated160 mg/1OralKaralex Pharma LLC2009-11-20Not applicableUs
FenofibrateTablet, film coated160 mg/1OralNu Care Pharmaceuticals,inc.2006-05-10Not applicableUs
FenofibrateTablet48 mg/1OralPerrigo New York Inc.2014-08-13Not applicableUs45802 0315 75 nlmimage10 243b921c
FenofibrateTablet160 mg/1OralPhysicians Total Care, Inc.2006-08-23Not applicableUs
FenofibrateCapsule130 mg/1OralApotex Corporation2013-07-26Not applicableUs
FenofibrateCapsule200 mg/1OralAmerincan Health Packaging2009-01-23Not applicableUs
FenofibrateTablet, film coated145 mg/1OralMylan Institutional2013-06-10Not applicableUs
FenofibrateTablet120 mg/1OralMylan Pharmaceuticals2016-06-23Not applicableUs
FenofibrateCapsule134 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateTablet160 mg/1OralProficient Rx LP2015-11-23Not applicableUs
FenofibrateTablet, film coated54 mg/1OralRanbaxy Inc.2006-05-10Not applicableUs63304 0900 90 nlmimage10 b53b5afa
FenofibrateTablet, film coated54 mg/1OralNucare Pharmaceuticals, Inc.2006-05-10Not applicableUs
FenofibrateCapsule200 mg/1OralMylan Pharmaceuticals2012-10-23Not applicableUs00378 8630 77 nlmimage10 263e9364
FenofibrateTablet, film coated160 mg/1Oralbryant ranch prepack2006-05-10Not applicableUs
FenofibrateCapsule67 mg/1OralRemedy Repack2015-11-27Not applicableUs
FenofibrateTablet160 mg/1OralA S Medication Solutions2010-02-012017-06-20Us
FenofibrateTablet48 mg/1OralLupin Pharmaceuticals2012-07-13Not applicableUs
FenofibrateTablet, film coated160 mg/1OralAphena Pharma Solutions Tennessee, Inc.2006-05-10Not applicableUs
FenofibrateTablet54 mg/1OralKaiser Foundations Hospitals2011-08-03Not applicableUs
FenofibrateCapsule67 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet48 mg/1OralA S Medication Solutions2014-08-132017-06-20Us
FenofibrateTablet, film coated160 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-01-13Not applicableUs
FenofibrateCapsule134 mg/1OralRhodes Pharmaceuticals, L.P.2017-06-01Not applicableUs
FenofibrateTablet145 mg/1OralAmerincan Health Packaging2013-01-15Not applicableUs68180 0361 09 nlmimage10 e54072d3
FenofibrateTablet160 mg/1OralAv Pak2015-08-13Not applicableUs
FenofibrateCapsule43 mg/1OralDr Reddy's Laboratories2014-04-07Not applicableUs
FenofibrateCapsule134 mg/1OralSt. Marys Medical Park Pharmacy2014-04-21Not applicableUs
FenofibrateCapsule67 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateCapsule43 mg/1OralRanbaxy Inc.2015-03-02Not applicableUs
FenofibrateTablet160 mg/1OralLupin Pharmaceuticals2015-11-11Not applicableUs
FenofibrateTablet48 mg/1OralAv Pak2016-09-19Not applicableUs
FenofibrateCapsule43 mg/1OralMylan Pharmaceuticals2013-02-22Not applicableUs
FenofibrateTablet, film coated160 mg/1OralProficient Rx LP2006-05-10Not applicableUs
FenofibrateCapsule67 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2017-04-07Not applicableUs
FenofibrateCapsule67 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-02-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralRhodes Pharmaceuticals, L.P.2017-06-01Not applicableUs
FenofibrateTablet, coated48 mg/1OralNorth Star Rx Llc2017-07-15Not applicableUs
FenofibrateCapsule130 mg/1OralAv Kare, Inc.2015-12-14Not applicableUs
FenofibrateTablet48 mg/1OralLupin Pharmaceuticals2012-07-13Not applicableUs
FenofibrateTablet, film coated160 mg/1OralMylan Pharmaceuticals2009-12-22Not applicableUs00378 7101 77 nlmimage10 6e49b72d
FenofibrateTablet48 mg/1OralCipla Limited2016-12-15Not applicableUs
FenofibrateCapsule67 mg/1OralCipla Limited2017-03-30Not applicableUs
FenofibrateTablet54 mg/1OralAv Kare, Inc.2015-03-31Not applicableUs
FenofibrateCapsule134 mg/1OralRemedy Repack2011-04-132017-03-03Us
FenofibrateTablet54 mg/1OralPhysicians Total Care, Inc.2006-11-15Not applicableUs
FenofibrateCapsule67 mg/1OralSt. Marys Medical Park Pharmacy2013-05-02Not applicableUs
FenofibrateTablet54 mg/1OralAmerincan Health Packaging2014-10-20Not applicableUs
FenofibrateTablet160 mg/301OralNorthwind Pharmaceuticals2014-05-07Not applicableUs
FenofibrateTablet, film coated48 mg/1OralCamber Pharmaceuticals2016-07-14Not applicableUs
FenofibrateCapsule200 mg/1OralImpax Generics2010-02-01Not applicableUs00115 0533 01 nlmimage10 9405ca2e
FenofibrateTablet, coated48 mg/1OralAurobindo Pharma2016-05-05Not applicableUs
FenofibrateTablet, film coated160 mg/1OralRanbaxy Inc.2006-05-10Not applicableUs
FenofibrateTablet145 mg/1OralA S Medication Solutions2014-09-232017-06-20Us
FenofibrateCapsule200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-02-01Not applicableUs
FenofibrateTablet54 mg/1Oralbryant ranch prepack2010-02-01Not applicableUs
FenofibrateTablet, film coated160 mg/1OralRemedy Repack2015-05-20Not applicableUs
FenofibrateTablet145 mg/1OralLupin Pharmaceuticals2012-07-13Not applicableUs
FenofibrateTablet160 mg/1OralA S Medication Solutions2010-02-012017-06-20Us
FenofibrateTablet, film coated48 mg/1OralMylan Pharmaceuticals2013-05-21Not applicableUs
FenofibrateCapsule134 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateTablet160 mg/1OralNucare Pharmaceuticals, Inc.2015-11-23Not applicableUs
FenofibrateCapsule134 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-02-01Not applicableUs
FenofibrateCapsule200 mg/1OralRhodes Pharmaceuticals, L.P.2017-06-01Not applicableUs
FenofibrateTablet54 mg/1OralImpax Generics2010-02-01Not applicableUs
FenofibrateCapsule134 mg/1OralUnit Dose Services2010-02-01Not applicableUs
FenofibrateCapsule130 mg/1OralDr Reddy's Laboratories2014-04-07Not applicableUs55111 0395 30 nlmimage10 c14060d3
LofibraCapsule200 mg/1OralTeva Select Brands2002-09-032017-10-31Us57844 0324 01 nlmimage10 db366de3
LofibraCapsule67 mg/1OralTeva Select Brands2002-10-112018-05-31Us57844 0322 01 nlmimage10 e2367113
LofibraTablet, film coated54 mg/1OralTeva Select Brands2005-11-232018-04-30Us57844 0691 98 nlmimage10 88364442
LofibraCapsule134 mg/1OralTeva Select Brands2002-09-032018-07-31Us57844 0323 01 nlmimage10 cf3667e3
LofibraTablet, film coated160 mg/1OralTeva Select Brands2005-11-232018-04-30Us57844 0692 98 nlmimage10 273613e0
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FenogalSMB Laboratories
LipanthylAbbott
LipantilNot Available
Lipidillbirn
Brand mixtures
NameLabellerIngredients
CholibAbbott
Categories
UNIIU202363UOS
CAS number49562-28-9
WeightAverage: 360.831
Monoisotopic: 360.112836867
Chemical FormulaC20H21ClO4
InChI KeyYMTINGFKWWXKFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
IUPAC Name
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
SMILES
CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Pharmacology
Indication

For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Structured Indications
Pharmacodynamics

Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

Mechanism of action

Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.

TargetKindPharmacological actionActionsOrganismUniProt ID
Peroxisome proliferator-activated receptor alphaProteinyes
agonist
HumanQ07869 details
MetalloproteinaseProteinunknown
inhibitor
HumanO43923 details
Peroxisome proliferator-activated receptor gammaProteinunknownNot AvailableHumanP37231 details
Peroxisome proliferator-activated receptor deltaProteinunknownNot AvailableHumanQ03181 details
Nuclear receptor subfamily 1 group I member 2Proteinunknown
partial agonist
HumanO75469 details
Related Articles
Absorption

Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide

Volume of distribution
  • 95 L [moderate renal impairment (creatinine clearance of 50 to 90 mL/min)]
  • 30 L [healthy adults]
Protein binding

~99% (Serum protein binding)

MetabolismNot Available
Route of elimination

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.

Half life

20 hours

Clearance
  • 1.2 L/h [Eldery]
Toxicity

LD50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcenocoumarolFenofibrate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideFenofibrate may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AmiodaroneThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Fenofibrate.Approved
AprepitantThe serum concentration of Fenofibrate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Fenofibrate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fenofibrate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Atorvastatin.Approved
BexaroteneThe serum concentration of Fenofibrate can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Fenofibrate can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Fenofibrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fenofibrate can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe metabolism of Fenofibrate can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Fenofibrate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Cerivastatin.Withdrawn
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibrate.Approved
ChlorpropamideFenofibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClarithromycinThe metabolism of Fenofibrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fenofibrate can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Fenofibrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Fenofibrate can be decreased when combined with Cobicistat.Approved
ColchicineFenofibrate may increase the myopathic rhabdomyolysis activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Fenofibrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Fenofibrate can be decreased when combined with Crizotinib.Approved
CyclosporineCyclosporine may increase the nephrotoxic activities of Fenofibrate.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Fenofibrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Fenofibrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Fenofibrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Fenofibrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fenofibrate can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Fenofibrate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DicoumarolFenofibrate may increase the anticoagulant activities of Dicoumarol.Approved
DihydroergotamineThe metabolism of Fenofibrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Fenofibrate can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Fenofibrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fenofibrate can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Fenofibrate can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Fenofibrate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Fenofibrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateFenofibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Fenofibrate can be decreased when it is combined with Etravirine.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Ezetimibe.Approved
FluconazoleThe metabolism of Fenofibrate can be decreased when combined with Fluconazole.Approved
FluindioneFenofibrate may increase the anticoagulant activities of Fluindione.Investigational
FluvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Fenofibrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fenofibrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fenofibrate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fenofibrate can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Fenofibrate can be increased when it is combined with Fusidic Acid.Approved
GlibornurideFenofibrate may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideFenofibrate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFenofibrate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFenofibrate may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneFenofibrate may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideFenofibrate may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideFenofibrate may increase the hypoglycemic activities of Glyburide.Approved
IdelalisibThe serum concentration of Fenofibrate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fenofibrate can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Fenofibrate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Fenofibrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Fenofibrate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Fenofibrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fenofibrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Fenofibrate can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Fenofibrate can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Fenofibrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Fenofibrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fenofibrate can be increased when combined with Lumacaftor.Approved
MevastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Mevastatin.Experimental
MifepristoneThe serum concentration of Fenofibrate can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Fenofibrate can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Fenofibrate can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Fenofibrate can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe metabolism of Fenofibrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fenofibrate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fenofibrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fenofibrate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Fenofibrate can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Fenofibrate can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Fenofibrate can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Fenofibrate can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Fenofibrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenindioneFenofibrate may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Fenofibrate can be increased when combined with Phenobarbital.Approved
PhenprocoumonFenofibrate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Fenofibrate can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pitavastatin.Approved
PosaconazoleThe metabolism of Fenofibrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin.Approved
PrimidoneThe metabolism of Fenofibrate can be increased when combined with Primidone.Approved, Vet Approved
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Fenofibrate.Approved
RanolazineThe metabolism of Fenofibrate can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Fenofibrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fenofibrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fenofibrate can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Fenofibrate can be decreased when combined with Ritonavir.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Rosuvastatin.Approved
SaquinavirThe metabolism of Fenofibrate can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Fenofibrate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fenofibrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fenofibrate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Simvastatin.Approved
St. John's WortThe serum concentration of Fenofibrate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Fenofibrate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Fenofibrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusTacrolimus may increase the nephrotoxic activities of Fenofibrate.Approved, Investigational
TelaprevirThe metabolism of Fenofibrate can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Fenofibrate can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Fenofibrate can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Fenofibrate can be decreased when it is combined with Tocilizumab.Approved
TolazamideFenofibrate may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideFenofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Coenzyme Q10.Experimental
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibrate.Approved, Investigational
VenlafaxineThe metabolism of Fenofibrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fenofibrate can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Fenofibrate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinFenofibrate may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe metabolism of Fenofibrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Increased absorption- take with meals.
References
Synthesis Reference

Jean-Francois Boyer, "Medicine based on fenofibrate, and a method of preparing it." U.S. Patent US4800079, issued January, 1988.

US4800079
General References
  1. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther. 2004 Apr;42(4):212-7. [PubMed:15124979 ]
  2. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61. [PubMed:16310551 ]
External Links
ATC CodesC10BA04 — Simvastatin and fenofibrateC10BA03 — Pravastatin and fenofibrateC10AB05 — Fenofibrate
AHFS Codes
  • 24:06.06
PDB EntriesNot Available
FDA labelDownload (283 KB)
MSDSDownload (19.3 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers7
1CompletedBasic ScienceHypercholesterolaemia1
1CompletedBasic SciencePharmacokinetic Variables1
1CompletedOtherFenofibrate / Glucuronosyltransferase / HIV Disease / Hypertriglyceridemias / Protease Inhibitors1
1CompletedTreatmentAdverse Events / Pharmacokinetic Variables1
1CompletedTreatmentAdverse Events / Pharmacokinetics1
1CompletedTreatmentDyslipidemia, Renal Insufficiency1
1CompletedTreatmentDyslipidemias1
1CompletedTreatmentHealthy Volunteers6
1CompletedTreatmentPharmacokinetics1
1RecruitingTreatmentHealthy Volunteers1
1Unknown StatusTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemia (Fredrickson Type Ⅱb)1
1WithdrawnTreatmentBMI >30 kg/m21
1, 2CompletedTreatmentDyslipidemias1
1, 2RecruitingTreatmentPrimary Biliary Cirrhosis (PBC)1
1, 2TerminatedTreatmentPrimary Sclerosing Cholangitis (PSC)1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2CompletedNot AvailableAlcoholism1
2CompletedDiagnosticHealthy Volunteers1
2CompletedDiagnosticMetabolic Syndromes1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentDyslipidemias2
2CompletedTreatmentDyslipidemias / Hypertriglyceridemias1
2CompletedTreatmentHIV-1 Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypertriglyceridemias1
2CompletedTreatmentHyperlipidemias2
2CompletedTreatmentHypertriglyceridemias / Non-alcoholic Fatty Liver Disease (NAFLD1
2CompletedTreatmentInsulin Resistance / Minor burns1
2CompletedTreatmentNon Familial Chylocmicronemia Syndrome (Non-FCS)1
2CompletedTreatmentPatients With Metabolic Syndrome1
2CompletedTreatmentPatients With Type 2 Diabetes1
2CompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
2RecruitingTreatmentHypercholesterolaemia1
2RecruitingTreatmentMedulloblastomas1
2TerminatedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Dyslipidemias / Sleep Apnea Syndrome1
2TerminatedTreatmentMetabolic X Syndrome Dyslipidemia1
2WithdrawnTreatmentPrimary Biliary Cirrhosis (PBC)1
2, 3CompletedTreatmentDyslipidemia/Glucose Metabolism Disorder1
2, 3CompletedTreatmentMinor burns1
2, 3RecruitingTreatmentDyslipidemias / Spinal Cord Injuries (SCI)1
2, 3RecruitingTreatmentMinor burns1
2, 3TerminatedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
2, 3WithdrawnTreatmentMinor burns1
3Active Not RecruitingTreatmentHypercholesterolaemia1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionRetinopathy, Diabetic1
3CompletedTreatmentCardiovascular Disease (CVD)1
3CompletedTreatmentCombined (Atherogenic) Dyslipidemia / Coronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia1
3CompletedTreatmentCombined Hyperlipidemia1
3CompletedTreatmentCoronary Artery Disease / Coronary Heart Disease (CHD) / Dyslipidemias1
3CompletedTreatmentCoronary Heart Disease (CHD) / Dyslipidemias / Mixed hypercholesterolemia4
3CompletedTreatmentDyslipidemia/Glucose Metabolism Disorder1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia1
3CompletedTreatmentDyslipidemias / Kidney Diseases1
3CompletedTreatmentDyslipidemias / Type 2 Diabetes Mellitus1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
3CompletedTreatmentHyperlipidemias5
3CompletedTreatmentHyperlipoproteinemias1
3CompletedTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentMixed hypercholesterolemia1
3RecruitingTreatmentCoronary Artery Disease1
3RecruitingTreatmentPrimary Biliary Cirrhosis (PBC)2
3RecruitingTreatmentSevere Hypertriglyceridemia2
3TerminatedDiagnosticCoronary Artery Atherosclerosis1
3TerminatedTreatmentHyperlipoproteinemia Type III1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 1 / Diabetic Nephropathies / Retinal Disorders1
3Unknown StatusTreatmentMixed hypercholesterolemia2
3WithdrawnTreatmentHypertriglyceridemias1
4Active Not RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypertriglyceridemias / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentHyperlipidemias / Sexual Dysfunctions1
4CompletedNot AvailableDyslipidemias / Vascular Diseases1
4CompletedNot AvailableHypertriglyceridemias / Insulin Resistance1
4CompletedBasic ScienceDyslipidemias1
4CompletedPreventionCholesterol, HDL1
4CompletedPreventionDyslipidemias / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Hypertriglyceridemias / Lipid Disorders1
4CompletedTreatmentCardiovascular Disease (CVD) / Dyslipidemias / Hypertriglyceridemias1
4CompletedTreatmentCoronary Heart Disease (CHD) / Hyperlipidemias1
4CompletedTreatmentDyslipidemias2
4CompletedTreatmentFenofibrate/Simvastatin Comparison1
4CompletedTreatmentHypercholesterolaemia / Hyperlipidemia, Familial Combined1
4CompletedTreatmentHypertensive1
4CompletedTreatmentHypertriglyceridemias3
4CompletedTreatmentInsulin Resistance / Metabolic Syndromes1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypercholesterolaemia1
4TerminatedPreventionDyslipidemias1
4TerminatedTreatmentHypertriglyceridemia in Type 4 Hyperlipidemia / Non Diabetic Subjects With Normoglycemia1
4TerminatedTreatmentSecond or Third Degree Burns1
4Unknown StatusBasic ScienceDiabetes / Retinopathy, Diabetic1
4Unknown StatusTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias1
4Unknown StatusTreatmentMicroalbuminuria1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceMetabolic Syndromes / Prediabetic State1
Not AvailableCompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Heart Diseases / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias / Hypertriglyceridemias / Insulin Resistance1
Not AvailableCompletedTreatmentCoronary Arteriosclerosis / Genetic Diseases, Inborn / Hypoalphalipoproteinemias1
Not AvailableCompletedTreatmentHyperlipidemias1
Not AvailableCompletedTreatmentHypertriglyceridemia With the Metabolic Syndrome1
Not AvailableCompletedTreatmentHypertriglyceridemias / Insulin Resistance1
Not AvailableCompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
Not AvailableCompletedTreatmentMixed hypercholesterolemia / Type 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentDiabetes Complications / Type 2 Diabetes Mellitus1
Not AvailableTerminatedBasic ScienceDiabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableTerminatedBasic ScienceFatty Liver1
Not AvailableTerminatedBasic ScienceFatty Liver / Insulin Resistance1
Not AvailableTerminatedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentMetabolic Syndromes1
Not AvailableTerminatedTreatmentPolycystic Ovaries Syndrome1
Not AvailableUnknown StatusBasic ScienceCardiovascular Disease (CVD)1
Not AvailableUnknown StatusBasic ScienceCytokines / Diabetes / Dyslipidemias / Inflammatory Reaction1
Not AvailableWithdrawnTreatmentTissue Lipid Metabolism1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral30 mg/1
CapsuleOral90 mg/1
CapsuleOral200 mg
CapsuleOral67 mg
TabletOral100 mg
TabletOral160 mg
TabletOral200 mg
CapsuleOral100 mg
Tablet, film coatedOral
CapsuleOral130 mg/1
CapsuleOral134 mg/1
CapsuleOral150 mg/1
CapsuleOral200 mg/1
CapsuleOral43 mg/1
CapsuleOral50 mg/1
CapsuleOral67 mg/1
TabletOral120 mg/1
TabletOral145 mg/301
TabletOral160 mg/1
TabletOral160 mg/301
TabletOral40 mg/1
TabletOral54 mg/1
Tablet, coatedOral145 mg/1
Tablet, coatedOral160 mg/1
Tablet, coatedOral48 mg/1
Tablet, coatedOral54 mg/1
Tablet, film coatedOral145 mg/1
Tablet, film coatedOral160 mg/1
Tablet, film coatedOral48 mg/1
Tablet, film coatedOral54 mg/1
CapsuleOral160 mg
TabletOral48 mg
TabletOral145 mg
TabletOral145.0 mg
TabletOral48.0 mg
TabletOral145 mg/1
TabletOral48 mg/1
Prices
Unit descriptionCostUnit
Triglide 160 mg tablet6.39USD tablet
Fenoglide 120 mg tablet5.17USD tablet
Antara 130 mg capsule5.13USD capsule
Tricor 145 mg tablet4.69USD tablet
Lipofen 150 mg capsule3.55USD capsule
Lofibra 200 mg capsule3.25USD capsule
Lofibra 160 mg tablet3.11USD tablet
Fenofibrate Micronized 200 mg capsule2.77USD capsule
Fenofibrate 160 mg2.47USD tablet
Fenofibrate 160 mg tablet2.38USD tablet
Lofibra 134 mg capsule2.03USD capsule
Antara 43 mg capsule1.8USD capsule
Fenofibrate Micronized 134 mg capsule1.79USD capsule
Fenoglide 40 mg tablet1.72USD tablet
Tricor 48 mg tablet1.63USD tablet
Triglide 50 mg tablet1.49USD tablet
Lipidil Supra 160 mg Tablet1.4USD tablet
Lofibra 67 mg capsule1.26USD capsule
Lipidil Micro 200 mg Capsule1.23USD capsule
Lipidil Supra 100 mg Tablet1.22USD tablet
Apo-Feno-Micro 200 mg Capsule1.14USD capsule
Fenofibrate Micro 200 mg Capsule1.14USD capsule
Mylan-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Novo-Fenofibrate Micronized 200 mg Capsule1.14USD capsule
Pms-Fenofibrate Micro 200 mg Capsule1.14USD capsule
Ratio-Fenofibrate Mc 200 mg Capsule1.14USD capsule
Fenofibrate Micronized 67 mg capsule1.0USD capsule
Lofibra 54 mg tablet0.99USD tablet
Fenofibrate 54 mg tablet0.81USD tablet
Apo-Feno-Super 160 mg Tablet0.79USD tablet
Novo-Fenofibrate-S 160 mg Tablet0.79USD tablet
Sandoz Fenofibrate S 160 mg Tablet0.79USD tablet
Apo-Feno-Super 100 mg Tablet0.68USD tablet
Novo-Fenofibrate-S 100 mg Tablet0.68USD tablet
Sandoz Fenofibrate S 100 mg Tablet0.68USD tablet
Apo-Fenofibrate 100 mg Capsule0.64USD capsule
Apo-Feno-Micro 67 mg Capsule0.45USD capsule
Novo-Fenofibrate Micronized 67 mg Capsule0.45USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2219475 No2002-07-092017-12-11Canada
CA2487054 No2008-03-182023-05-23Canada
US5145684 No1994-01-252011-01-25Us
US6074670 No1998-01-092018-01-09Us
US6277405 No1998-01-092018-01-09Us
US6375986 No2000-09-212020-09-21Us
US6589552 No1998-01-092018-01-09Us
US6652881 No1998-01-092018-01-09Us
US6696084 No2001-09-112021-09-11Us
US7037529 No1998-01-092018-01-09Us
US7041319 No1998-01-092018-01-09Us
US7101574 No2000-08-202020-08-20Us
US7276249 No2003-02-212023-02-21Us
US7320802 No2003-02-212023-02-21Us
US7658944 No2004-12-092024-12-09Us
US7863331 No2000-08-082020-08-08Us
US8026281 No2005-04-222025-04-22Us
US8124125 No2004-10-012024-10-01Us
US8481078 No2004-10-012024-10-01Us
US9173847 No2004-10-012024-10-01Us
US9314447 No2013-05-312033-05-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)80.5 °CPhysProp
water solubility0.25mg/ml at 25 °CNot Available
logP5.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000707 mg/mLALOGPS
logP4.86ALOGPS
logP5.28ChemAxon
logS-5.7ALOGPS
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.13 m3·mol-1ChemAxon
Polarizability38.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier+0.9334
Caco-2 permeable+0.648
P-glycoprotein substrateNon-substrate0.5571
P-glycoprotein inhibitor INon-inhibitor0.5995
P-glycoprotein inhibitor IINon-inhibitor0.7632
Renal organic cation transporterNon-inhibitor0.9042
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9147
CYP450 3A4 substrateSubstrate0.6735
CYP450 1A2 substrateInhibitor0.7599
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.7619
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7088
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6373
BiodegradationNot ready biodegradable0.9918
Rat acute toxicity2.2250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.9083
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0090000000-f4e7816cd30c8701cce3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0029000000-60bbd2de375b9b56ec55View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0190000000-6e83f7c906eaeb363cafView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0019-0930000000-fccf28abf1a426a6949bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-07739caadc1c26a7baaaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-5045a0039b18e3d7dd9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-1900000000-25a145c2138d34aa4b52View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-0029000000-a98245ce05ccb6a6707eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0190000000-4e9b3e71fc7960db389eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0019-0930000000-9d3908b5ee8b5f59218dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-1090af5e239a872654d9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-0900000000-5dcab26837d06f9756f8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-000i-1900000000-2663fed5f3ba78d3c7a5View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-001i-0090000000-4933bea6ce44715c6172View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-01qi-0595000000-d3c4c1cce3b5e1fbb33fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-01qi-1594000000-9756f301ee5d44577654View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-000i-3920000000-91103d7fd9d1063bae9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-0019-0941000000-27e0cd2c4e952b499a9aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomChemical entities
Super ClassOrganic compounds
ClassBenzenoids
Sub ClassBenzene and substituted derivatives
Direct ParentBenzophenones
Alternative ParentsDiphenylmethanes / Aryl-phenylketones / Phenoxyacetic acid derivatives / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Carboxylic acid esters
SubstituentsBenzophenone / Aryl-phenylketone / Diphenylmethane / Phenoxyacetate / Phenoxy compound / Aryl ketone / Phenol ether / Benzoyl / Alkyl aryl ether / Chlorobenzene
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptorsaromatic ether, carboxylic ester, monochlorobenzenes, chlorobenzophenone (CHEBI:5001 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fa...
Gene Name:
PPARA
Uniprot ID:
Q07869
Uniprot Name:
Peroxisome proliferator-activated receptor alpha
Molecular Weight:
52224.595 Da
References
  1. Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49. [PubMed:10494028 ]
  2. Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50. [PubMed:10799317 ]
  3. Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4. [PubMed:11018525 ]
  4. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7. [PubMed:11342537 ]
  5. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71. [PubMed:11474486 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. [PubMed:10828060 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
mmp20
Uniprot ID:
O43923
Uniprot Name:
Matrix metalloproteinase-25
Molecular Weight:
20353.66 Da
References
  1. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F: Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension. 2007 May;49(5):1084-94. Epub 2007 Mar 12. [PubMed:17353509 ]
  2. Lebrasseur NK, Duhaney TA, De Silva DS, Cui L, Ip PC, Joseph L, Sam F: Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007 Sep;50(3):489-96. Epub 2007 Jul 2. [PubMed:17606858 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Uniprot Name:
Peroxisome proliferator-activated receptor gamma
Molecular Weight:
57619.58 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as ...
Gene Name:
PPARD
Uniprot ID:
Q03181
Uniprot Name:
Peroxisome proliferator-activated receptor delta
Molecular Weight:
49902.99 Da
References
  1. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. [PubMed:11779144 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Uniprot Name:
Nuclear receptor subfamily 1 group I member 2
Molecular Weight:
49761.245 Da
References
  1. Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29. [PubMed:20024649 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on July 25, 2017 17:54